Biological response modifiers in cancer

MedGenMed Medscape General Medicine

Volumn 8, Issue 4, 2006, Pages

  Reang, Purabi ^a   Gupta, Madhur ^b   Kohli, Kamlesh ^a  

^a LADY HARDINGE MEDICAL COLLEGE   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ADESLEUKIN; ALPHA INTERFERON; ALPHA2B INTERFERON; ANGIOGENESIS INHIBITOR; ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; BEVACIZUMAB; BIOLOGICAL RESPONSE MODIFIER; CD4 ANTIGEN; CD8 ANTIGEN; CISPLATIN; DACARBAZINE; DOPAMINE; FIBROBLAST GROWTH FACTOR; FLUOROURACIL; HISTAMINE H2 RECEPTOR ANTAGONIST; INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; PHENYLEPHRINE; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; THALIDOMIDE; TUMOR VACCINE; UNINDEXED DRUG; VASCULOTROPIN; CANCER VACCINE;

ADULT RESPIRATORY DISTRESS SYNDROME; ANEMIA; ANOREXIA; BACTERIAL INFECTION; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANDIDIASIS; CAPILLARY LEAK SYNDROME; CARDIOTOXICITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ADHESION; CELL DIFFERENTIATION; CELL MIGRATION; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; COMA; CONFUSION; DIARRHEA; DRUG ABSORPTION; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG USE; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; EOSINOPHILIA; ERYTHRODERMA; FLU LIKE SYNDROME; FLUID RETENTION; HEART ARRHYTHMIA; HEART INFARCTION; HERPES SIMPLEX; HUMAN; HYPOTENSION; IMMUNE RESPONSE; IMMUNOSTIMULATION; INTERSTITIAL NEPHRITIS; KIDNEY CARCINOMA; LETHARGY; LIVER DYSFUNCTION; LUNG ASPERGILLOSIS; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MILIARY TUBERCULOSIS; MYALGIA; MYOCARDITIS; NAUSEA; PNEUMOCYSTIS PNEUMONIA; RASH; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR CELL; UREMIA; ADOPTIVE IMMUNOTHERAPY; IMMUNOLOGY; METHODOLOGY; NEOPLASM;

ANTIBODIES, MONOCLONAL; BIOLOGICAL RESPONSE MODIFIERS; CANCER VACCINES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS;

EID: 33751219595     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (127)

1. Dealtry GB, Naylor MS, Fiers W, Balkwill FR. DNA fragmentation and cytotoxicity caused by TNF is enhanced by IFN- gamma. Eur J Immunol. 1987; 17:689-693. Abstract
2. Bregman MD, Meyskens FL Jr. Human recombinant alpha and gamma IFNs enhance the cytotoxic properties of TNF on human melanoma. J Biol Exp Med. 1988;7:384-389.
3. Houghton AN, Thomson TM, Gross D, Oettgen HF, Old LJ. Surface antigens of melanoma and melanocytes. Specificity of induction of 1a antigens by human gamma- IFN. J Exp Med. 1984:160:255-269. Abstract
4. Sayers TJ, Mason AT, Ortaldo JR. regulation of human natural killer cell activity by IFN gamma; lack of role in IL-2 mediated augmentation. J Immunol. 1986:136:2176-2180. Abstract
5. Mittleman A, Krown SE, Cirrincione C, et al. Analysis of T cell subsets on cancer patients treated with interferon. Am J Med. 1983;75:966-972. Abstract
6. Hakansson A, Gustafsson B, Krysander L, Hakansson L. Tumour infiltrating lymphocytes in metastatic malignant melanoma and response to IFN alpha treatment. Br J Cancer. 1996:74:670-676. Abstract
7. Folkman J. Successful treatment of an angiogenic disease. N Engl J Med. 1989:320:1211-1212. Abstract
8. Dinney CPN, Bielenberg DR, Perrotte P, et al. Inhibition of basic FGF expression, angiogenesis and growth of human bladder carcinoma in mice by systemic IFN alpha administration. Cancer Res. 1998;58:808-814. Abstract
9. Thompson JA, Cox WW, Lindgren CG, et al. Subcutaneous recombinant gamma interferon in cancer patients: toxicity, pharmacokinetics and immunomodulatory effects. Cancer Immunol Immunother. 1987;25:47-53. Abstract
10. Coates A, Railings M, Hersey P, Swanson C. Phase II study of recombinant alpha-2 interferon in advanced malignant melanoma. J Interferon Res. 1986;6:1-4.
11. Steiner A, Wolf C, Pehamberger H. comparison of the effects of three different treatment regimens of recombinant IFNs (r-IFN alpha, r -IFN gamma and r-IFN alpha + cimetidine) in disseminated malignant melanoma. J Cancer Res Clin Oncol. 1987; 113:459-465. Abstract
12. Kirkwood JM, Emstoff MS, Davis CA, et al. Comparison of intramuscular and intravenous recombinant alpha-2 IFN in melanoma and other cancers. Ann Inter Med. 1985;103:32-36.
13. Creagan ET, Ahman DL, Frytak S, et al. Three consecutive phase II studies of recombinant IFN-alpha2a in advanced malignant melanoma. Cancer. 1987;59:638-640. Abstract
14. Evans LM, Itri LM, Campion M, et al. IFN-alpha 2a in the treatment of AIDS related Kaposi sarcoma. J Immunother. 1991;10:39-50. Abstract
15. Spielberger RT, Mick R, Retain MJ, Golomb H. IFM treatment for hairy cell leukemia: an update on a cohort of 69 patients treated from 1983-1986. Leukemia Lymphoma. 1994;14:89-93. Abstract
16. Morgan D, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal bone marrow. Science. 1976; 193:1007-1008. Abstract
17. Lotze MT, Grimm EA, Mazumdar A, Strausser JL, Rosenberg SA. Lysis of fresh and cultured autologous tumour by human lymphocytes cultured in T cell growth factor. Cancer Res. 1981;41:4420-4425 Abstract
18. Grimm EA. Mazumdar A, Zhang HZ, Rosenberg SA. Lymphokine activated killing phenomenon: lysis of natural killer resistant fresh solid tumour cells by IL-2 activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155:1823-1841. Abstract
19. Lafreniere R, Rosenberg SA. Adoptive immunotherapy of murine hepatic metastasis with LAK cells and recombinant IL2 can mediate the regression of both immunogenic and non immunogenic sarcomas and adenocarcinomas. J Immunol. 1985;135:4273-4280. Abstract
20. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high dose bolus IL-2. JAMA. 1994;271:907-913. Abstract
21. Dutcher JP, Creekmore S, Weiss GR, et al. A phase II study of IL-2 and LAK cells in patients with metastatic malignant melanoma. J Clin Oncol. 1989;7:477-485. Abstract
22. Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high dose IL-2 alone or in conjunction with LAK cells for treatment of patients with advanced cancer. J Natl Cancer Inst. 1993;8:622-632.
23. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using LAK cells and IL-2 or high dose IL-2 alone. N Engl J Med. 1987;316:889-897 Abstract
24. Schwartzemtruber DJ. Biologic therapy with IL-2. Clinical applications: principles of administration and management of side effects. In: De Vita V, Hallman S, Rosenberg SA, eds. Biologic Therapy of Cancer. 2nd ed. Philadelphia, Pa: JB Lippincott; 1995:235-249.
25. Klempner M, Noring R, Mier J, Alkins MB. An acquired neutrophil chemotactic defect in patients receiving immunotherapy with IL-2. N Engl J Med. 1990;322:959-965. Abstract
26. Kammula US, White DE, Rosenberg SA. Trends in the safety of high dose bolus IL-2 administration in patients with metastatic cancer. Cancer. 1998;83:797-805. Abstract
27. Legha SS, Gianan MA, Plager C, et al. Evaluation of IL-2 administered by continuous infusion in patients with metastatic melanoma. Cancer. 1996;77:89-96. Abstract
28. Yang JC, Rosenberg SA. An ongoing prospective randomized comparison of IL-2 regimens for treatment of metastatic renal cell carcinoma. Cancer J Sci Am. 1997;3:S79-S84. Abstract
29. Sleiffer DT, Janssen RAJ, Buter T, et al. Phase II study of subcutaneous IL02 in unselected patients with advanced renal cell carcinoma on an outpatient basis. J Clin Oncol. 1992;10:1119-1123. Abstract
30. Atkins MB, Shet A, Sosman JA. IL-2 Clinical applications: melanoma. In: Rosenberg SA, ed. Principles and Practice of Biologic Therapy of Cancer. 3rd ed Philadelphia, Pa: Lippincott Williams and Wilkins; 2000.
31. Marincola FM, White DE, Wize AP, Rosenberg SA. Combination therapy with IFN alpha2a and IL-2 for treatment of metastatic cancer. J Clin Oncol. 1995;13:1110-1122. Abstract
32. Sosman J, Weiss G, Margolin K, et al. Phase IB clinical trial of anti-CD3 followed by high dose IL-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunological effects. J Clin Oncol. 1993;11:1496-1505. Abstract
33. Atzpodien J, Kirchner H, Hanninem EL, et al. IL-2 in combination with IFN alpha and 5- FU for metastatic RCC. Eur J Cancer. 1993;29A(suppl 5):S6-S8 Abstract
34. Legha SS, Buzaid AC. Role of recombinant IL-2 in combination with IFN alpha and chemotherapy in treatment of advanced melanoma. Semin Oncol. 1993;2(suppl 9):27-32.
35. Ludwig H,. Fritz E, Leitgeb C, et al. Prediction of response to erythropoietin treatment in chronic anaemia of cancer. Blood. 1994;84:1056-1063. Abstract
36. Gerhartz HH, Engellhard M, Meusers P, et al. Randomized double blind, placebo controlled, Phase III study of recombinant human GM-CSF as adjuvant to induction treatment of high grade malignant non-Hodgkin's lymphoma. Blood. 1993;82:2329-2339. Abstract
37. Lieschke GJ, Burgess AW. Granulocyte CSF and GM-CSF91. N Engl J Med. 1992;327:28-35. Abstract
38. Kohler G, Milstein C. Continuous cultures of fused secreting antibody of redefined specificity. Nature. 1975;256:495-497. Abstract
39. Kudo T, Saeki T, Tachibana T. A simple and improved method to generate human hybridomas. J Immunol Methods. 1991;145:119-125. Abstract
40. Riethmuller G, Holz E, Schlimok G, et al. Monoclonal antibody therapy for resected Duke colorectal cancer: seven year outcome of a multicenter randomized trial. J Clin Oncol. 1998;6;1788-1794.
41. Lamon D, Clark G, Wong S, et al. Human breast cancer: correlation of relapse and survival with amplification of he HER-2/neu oncogene. Science. 1987;235:177-182. Abstract
42. Khazaeli MB, Conry RM, Lo Buglio AF. Human immune response to monoclonal antibody. J Immunother. 1994; 15:42-52. Abstract
43. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2. N Engl J Med. 2001;344:783-792. Abstract
44. Mayer A, Takimoto M, Fritz E, et al. The prognostic significance of proliferating cell nuclear antigen, EGFR and mdr gene expression in colorectal cancer. Cancer. 1993;71:2454-2460. Abstract
45. Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of EGFR by cetuximab. Cancer Cell. 2005;7:301-311. Abstract
46. Saltz L, Kies M, Abbruzzese JI et al. The presence and intensity of cetuximab induced acne like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol. 2003;22:204a(abstract).
47. Lenzavecchia A, Scheidegger D. The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur J Immunol. 1987;17:105-111. Abstract
48. Kazaeli MB, Cenry RM, Lo Buglio AF. Human immune response to monoclonal antibodies. J Immunother. 1994;15:42-52. Abstract
49. Davis T, Maloney D, Czerwinski D, et al. Anti-idiotype antibodies can induce long term complete remissions in non-Hodgkins lymphoma without eradicating malignant clone. Blood. 1998; 92:1184-1190. Abstract
50. Maloney D, Levy R, Miller R. Monoclonal anti-idiotype therapy of B cell lymphoma. Biol Ther Cancer. 1992 2:1-10.
51. Hale G, Xia M, Thige HP, et al. The CAMPATH antigen (CD52). Tissue Antigens. 1990;35:1-10. Abstract
52. Lundin J, Osterborg A, Brittinger G, et al. CAMPATH- 1H mAB in therapy for previously treated low grade NHL; a phase II multicenter study. J Clin Oncol. 1998;16:3257-3263. Abstract
53. Tang S, Hewitt K, Reis M, et al. Immunosuppressive toxicity of CAMPATH -I monoclonal antibody in treatment of patients with recurrent low grade lymphoma. Leukemia Lymphoma. 1996;24:93-101. Abstract
54. Press O, Appelbaum F, Ledbetter J, et al. Monoclonal antibody IF-5(anti CD -20) serotherapy of human B-cell lymphomas. Blood. 1987;69:484-491.
55. Mc Laughlin P, Grillo-Lopez A, Link B, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a 4 dose treatment programme. J Clin Oncol. 1998;16;2825-2833. Abstract
56. Mc Laughlin P, Grillo-Lopez A, White C, et al. Prognostic factors for NHL patients treated with chemotherapy may not predict response duration in patients treated with immunotherapy: rituximab experience. Proc Am Assoc Cancer Res. 1999;40:718-721.
57. Czuzman M. CHOP plus rituximab chemoimmunotherapy of indolent B- cell lymphoma. Semin Oncol. 1999;26:88-96. Abstract
58. Mc Laughlin P, Grillo lopez AJ, Link B, et al. Rituximab chimeric anti CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients relapsed to a four dose treatment programme. J Clin Oncol. 1998;16:2825-33. Abstract
59. Multani PS, Grossbard ML. Monoclonal antibody based therapies for hematologic malignancies. J Clin Oncol. 1998; 16:3691-3710. Abstract
60. Prestwich W, Nunes J, Kwok C. Beta dose point kernels for radionuclides of potential use in radioimmunotherapy. J Nucl Med. 1989;30:1036-1046. Abstract
61. Press OW. Radiolabelled antibody therapy of B-cell lymphomas. Semin Oncol. 1999;26:58-65. Abstract
62. Liu S, Early J, Petersdorf S, et al. Follow up of relapsed B- cell lymphoma treated with Iodine 131 labelled anti-CD20 antibody and autologous stem cell rescue. J Clin Oncol. 1998;16;3270-3278. Abstract
63. De Nardo G, De Nardo S, Kukis D, et al. Maximum tolerated dose of Cu-21T-BAT-LYM-I for fractionated radioimmunotherapy of non Hodgkins lymphoma: a pilot study. Anticancer Res. 1998;18:2779-2788. Abstract
64. De Nardo G, De Nardo S, Lamborn K, et al. Low dose fractionated radioimmunotherapy for B cell malignancies using 1131-LYM-1 antibody. Cancer Biother. 1998; 13:239-254.
65. Stein R, Belisle E, Hansen H, et al. Epitope specificity of the anti-B cell lymphoma monoclonal antibody. LL2. Cancer Immunol Immunother. 1993;37:293-298. Abstract
66. Juweid M, Stadtmaur E, Hajjar G, et al. Pharmacokinetics, doximetry and initial therapeutic results with 1311 and 111 In-90-Y-labeled humanized LL2 anti CD-22 monoclonal antibody in patients with relapsed, refractory non-Hodgkins lymphoma. Clin cancer Res. 1999;5:3292s-303s. Abstract
67. Caron P, Schwartz M, Co M, et al. Murine and humanized constructs of mAB M195(anti-CD 33) for therapy of acute myelogenous leukemia. Cancer. 1994;73(3suppl):1049-1056.
68. Witzig T, White C, Wiseman G, et al. Phase II/III trial of IDEC-42b8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell NHL. J Clin Oncol. 1999;17:3793-3803. Abstract
69. Gordon L, White C, Witzig T, et al. Zevalin[TM] (IDEC- Y2B8) radioimmunotherapy of rituximab refractory follicular non Hodgkins lymphoma (NHL): interim results. Blood. 1999;94:912-914.
70. Gordon MS, Margolin K, Tapaz M, et al. Phase I safety and p/k study of recombinant human anti-VEGF in patients with advanced cancer. J Clin Oncol. 2001;19:843-850. Abstract
71. Rosen LS. Clinical experience with angiogenesis signaling inhibitors ;focus on VEGF blockers. Cancer Control. 2002;9(suppl 2):36-44.
72. Jain RK. Tumour angiogenesis and accessibility: role of VEGF. Semin Oncol. 2003;29(suppl16):3-9.
73. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibits angiogenesis and suppress tumour growth. Nature. 1990;348:555-557. Abstract
74. Castronova V, Belotti D. TNP-470: mechanisms of action and early clinical development. Eur J Cancer. 1990;32A:2520-2527.
75. Pike SE, Yao L, Jones KD, et al. Vasostatin, a calreticular fragment inhibits angiogenesis and suppress tumour growth. J Exp Med. 1998; 188:239-256.
76. Ramachandran R, Dhanabab M, Volk R, et al. Antiangiogenic activity of restin, NC 10 domain of human collagen XV: comparison to endostatin. Biochem Biophys Res Commun. 1999;255:735-739. Abstract
77. Kim KJ. Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppress tumour growth in vivo. Nature. 1993;362:842-844.
78. Kohn EC, Liotta LA. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res. 1995;55:1856-1862. Abstract
79. Kohn EC, Alessandro R, Sponster J, et al. Angiogenesis: Role of calcium-mediated signal transduction. Proc Natl Acad Sci U S A. 1995;92:1307-1311. Abstract
80. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumour and lymphocyte induced vascular responses. Cancer Res. 1987;47:5135-5165.
81. Ezekowitz RA, Mulliken JB, Folkman J. IFN- alpha2a therapy for life threatening hemangiomas of infancy. N Engl J Med. 1992;326:1456-1463. Abstract
82. Brooks PC, Montgomery AMP, Rosenfeld M, et al. Integrin alphaVbeta 3 antagonists promote tumour regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157-1164. Abstract
83. Rasmussen HS, McCann PP. Matrix metalloproteinase inhibition as a novel anticancer strategy: A review with special focus on batimastat and marimastat. Pharmacol Ther. 1997;75:69-75. Abstract
84. Brown PD, Giavazzi R. Matrix metalloproteinase inhibition : A review of antitumour activity. Ann Oncol. 1995;6:967-974. Abstract
85. Zondor SD, Medina PJ. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother, 2004;38:1258-1264.
86. Chen HX, Gore-Langton RE, Cheson BD. Current clinical trials of the anti-VEGF monoclonal antibody bevacizumab. Oncology. 2001;15:1017-1026. Abstract
87. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer N Engl J Med. 2004;350:2335-2342.
88. Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in adhesion cascade. Immunopharmacology. 1996;31:213-221. Abstract
89. Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates VEGF secretion: therapeutic applications. Leukemia. 2001;15:1950-1961. Abstract
90. Davies F, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment NK cells cytotoxicity in multiple myeloma. Blood. 2001;98:210-216. Abstract
91. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogues in human multiple myeloma cells: therapeutic implications. Blood. 2002;99:4525-4530. Abstract
92. Palumbo A, Bertola A, Falco P, et al. Efficacy of low dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J. 2004;5:318-324. Abstract
93. Raza A, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in long standing refractory anemias of patients with myelodysplastic syndromes. Blood. 2001;98:958-965. Abstract
94. Amato R. Thalidomide therapy for renal cell carcinoma. Crit Rev Oncol Hematol. 2003;46:s59-s65. Abstract
95. Meples W. Advanced pancreatic cancer: a multi-institutional trial with gemcitabine and thalidomide. J Clin Oncol. 2004;22:abstract 4082.
96. Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen independent prostate cancer. J Clin Oncol. 2004;22:2532-2539. Abstract
97. Hynes NE, Horsch K, Olayioye A, Badache A. The ErbB receptor tyrosine family as signal integrators. Endocr Relat Cancer. 2000;8:151-159.
98. Baselga J, Arteaga CL. Critical update and emerging trends in EGFR targeting in cancer. J Clin Oncol. 2005;23:2445-2459. Abstract
99. Tracy S, Mukohara T, Hansen M, et al. Geftinib induces apoptosis in EGFRL858r NSCL cancer cell line H3255. Cancer Res. 2004;64:7241-7244. Abstract
100. Chu E, Sartorelli AC. Cancer chemotherapy. In: Katzung BG, ed. Basic and Clinical Pharmacology. 9th ed. New York: McGraw Hill; 2004:898-930.
101. Hirsch FR, Varella GM, Bunn PA Jr, et al. EGFR in NSCL carcinomas: correlation between gene copy and protein expression and impact on prognosis. J Clin Oncol. 2003;21:3798-3807. Abstract
102. Nicolson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37(suppl):s9-s15.
103. Cohem MH, Williams GA, Sridhara R, et al. FDA drug approval summary: geftinib(ZD1839)(Iressa) tablets. Oncologist. 2003;8:303-306. Abstract
104. Fukuoka H, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of geftinib for previously treated pts with advanced NSCL. J Clin Oncol. 2003;21:2237-2246. Abstract
105. Kris MG, Natale RB, Herbst RS, et al. Efficacy of geftinib an inhibitor of EGFR tyrosine kinase, in symptomatic patients with NSCL: a randomized controlled trial. JAMA. 2003;290:2149-2158. Abstract
106. Fumikata H, Motoi A, Hiroyoshi D, et al. Antitumour effect of geftinib(Iressa) on esophageal squamous cell ca cell lines in vitro and in vivo. Canc Lett. 2005;226:37-47.
107. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumour response and survival with erlotinib in patients with NSCL. J Clip Oncol. 2004;22:3238-3247. Abstract
108. Shepherd FA, Pareira JR, Ciulaenu T, et al. Erlotinib in previously treated NSCL. N Engl J Med. 2005;353:123-132. Abstract
109. Pardoll DM. Cancer vaccines. Nat Med. 1998;4:525-531. Abstract
110. Pardoll DM. Therapeutic vaccination for cancer. Clin Immunol. 2000;95:s44-s62. Abstract
111. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-52. Abstract
112. Sauter B, Albert ML, Francisco L, et al. Consequences of cell death : exposure to necrotic tumour cells but not primary tissue cells or apoptotic cells or apoptotic cells induces the maturation of immunostimulatory dendritic cells. J Exp Med. 2000;191:423-434. Abstract
113. Le Poole IC, Riker AJ, Quevedo ME, et al. Interferon gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T- cells. Am J Pathol. 2002; 160:521-528. Abstract
114. Gurunathan S, Irvine KR, Wu CY, et al. CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infections and tumour challenge. J Immunol. 1998;161:4563-71. Abstract
115. Felzman T, Buchberger M, Lehner M.et al. Functional maturation of dendritic cells by exposure to CD40 ligand transgenic tumour cells, fibroblasts or keratinocytes. Cancer Lett. 2001;50:125-133.
116. Sing G, Parker S, Hobart P. The development of bicistronic plasmid DNA vaccine for B-cell lymphoma. Vaccine. 2002;20:1400-1411. Abstract
117. Raun T, Gruber R, Riethmuller G, et al. Antiself antibodies selected from a human IgD heavy chain repertoire: a novel approach to generate therapeutic human antibodies against tumour associated differentiation antigens. Cancer Immunol Immunother. 2001;50:141-150. Abstract
118. Niethammer AG, Primus FJ, Xiang R, et al. An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice. Vaccine. 2001;20:421-429. Abstract
119. Gunn GR, Zubair A, Peters C, et al. Two listeria monocytogenes vaccine vectors that express different molecular forms of HPV-16 E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumours immortalized by HPV-16. J Immunol. 2001;167:6471-6479. Abstract
120. Pass HA, Schwartz SL, Wunderlick JR, et al. Immunization of patients with melanoma peptide vaccines :immunologic assessment using the ELISPOT assay. Cancer J Sci Am. 1998;4:316-323. Abstract
121. Neelapu SS, Basker S, Kwak LW. Detection of keyhole limpet hemocyanin (KLH)- specific immune responses by intracellular cytokine assay in patients vaccinated with idiotype KLH vaccine J Cancer Res Clin Oncol. 2001; 127 (suppl 2):R14-R19.
122. Coule PG, Karanikas V, Colau D, et al. A monoclonal cytolytic t lymphocyte response observed in a melanoma patient vaccinated with tumour specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci U S A. 2001;98:10290-10295. Abstract
123. Wallack MK, Sivanandham M, Balch CM, et al. Surgical adjuvant active specific immunotherapy for pts with stage III melanoma; the final analysis of data from phase III, randomized, double blind, multicenter vaccine melanoma oncosylate trial. J Am Coll Surg. 1998; 187:69-77. Abstract
124. Mitchell MS. Perspective on allogenic melanoma lysate in active specific immunotherapy. Semin Oncol. 1998;25:623-635. Abstract
125. Livingston PO, Wong GY, Adluri S, et al. Improved survival in stage II melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol. 1994; 12:1036-1044. Abstract
126. Harris JE, Ryan L, Hoover HCJ, et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumour cell vaccine: Eastern Cooperative Oncology group study E5283. J Clin Oncol. 2000; 18:148-157. Abstract
127. Vermorken JB, Classen AM, Van Timteren H, et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomized trial. Lancet. 1999;353:345-350. Abstract